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DURING the past decade, there has
been a renewed wave of interest in
tumour immunology and in particular in
the search for components or functions of
cancer cells not shared by their normal
counterparts. One goal has been to
elucidate if tumours do or do not con-
tain "tumour-specific or associated anti-
gens ".
Most of the investigations have been
effected using neoplasms of syngeneic
animals and have clearly demonstrated in
almost all tumours the existence of new
antigens which are absent in presently
detectable amounts from normal tissues
(Old and Boyse, 1964; Baldwin, 1970;
Stonehill and Bendich, 1970). While the
syngeneic donor-host relationship seldom
pertains in man, other experimental
methods have clearly shown that many
different types of human tumours, includ-
ing colonic (Gold and Freedman, 1965a),
ovarian (Levi, Keller and Mandl, 1969;
McNeil et al., 1969), bronchial (Yashi et al.,
1968), mammary (Edynak et al., 1971)
and urothelial carcinomata (Bubenik et al.,
1970), neuroblastoma (Hellstrom et al.,
1968), melanoma (Morton et al., 1968;
Jehn et al., 1970), lymphomata (Smith,
Klein and Klein, 1967; Klein et al., 1969,
Buff6 et al., 1970; Order, Porter and
Hellman, 1971), leukaemia (Harris et al.,
1971) and sarcomata (Morton et al., 1969;
Wood and Morton, 1971), have tumour-
associated antigens.
Ofgreat interest has been the discovery
of one particular group of materials,
namely " embryo-specific or foetal anti-
gens" in association with human (Gold
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and Freedman, 1965a; Tee, Wang and
Watkins, 1965; Yashi et al., 1968;
Hakkinen and Viikari, 1969; Abelev,
1971; Klavins, Mesa-Tejada and Weiss,
1971; Trouillas, 1971) and animal tumours
(Pearson and Freeman, 1968; Brawn,
1970; Coggin, Ambrose and Anderson,
1970; Duff and Rapp, 1970; Stonehill and
Bendich, 1970; Alexander, 1972). The
reappearance of embryo-specific materials
was first postulated in human neoplasms
as long ago as 1929 (Hirszfeld) and was
noted by Stonehill and Bendich (1970) in
diverse tumours of the mouse, rat and
hamster induced by physical, viral and
chemical agents, as well as those occurring
spontaneously. Stonehill and Bendich
(1970) proposed that this was a universal
oncological phenomenon which they
termed " retrogenetic expression ".
The observation that foetal antigens
could be released into the body fluids
from human tumours (Abelev, 1968;
Thomson et al., 1969) created a further
dimension in that such materials could
perhaps be of clinical value in the diag-
nosis and management of patients. To
be clinically useful, these macromolecules
would appear to require to fulfil 4 criteria:
(1) pass from the tumour into the body
fluids; (2) aid with the differential diagno-
sis of tumours by being found only with
tumours i.e. cancer specific and ifpossible,
site or tumour-type specific; (3) decline in
amounts with successful therapy and rise
again with recurrences; (4) be readily
measurable by methods applicable for
routine laboratory use.
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to discuss the association of foetal antigens
and human neoplasms and examine their
status in the diagnosis and management
of tumour-bearing patients. In addition,
attempts will be made to indicate those
aspects which the authors consider are
worthy of further intensive study or
which require clarification before they are
applied to the clinical situation.
Human tumour-associated foetal
macromolecules (antigens) fall into 2
principal categories, depending upon
whether or not they pass from the tumour
cells into the plasma and other body fluids
(Table I). Those which occur outside the
tumour may be further subdivided accord-
ing to the presence or absence of bio-
logical activity. Most of the article will
be devoted to discussing the carcino-
embryonic antigen (CEA) and a1-foeto-
protein (AFP) which are the 2 materials
whose role has been best elucidated.
TABLE I.-Human Tumour-Associated
Foetal Macromolecules (Antigens)
1. Present in tumours and body fluids
a. without known metabolic effects
Carcinoembryonic antigen (CEA).
(X1-Foetoprotein (AFP).
aC2H-Foetoprotein.
,BS-Foetoprotein.
Leukaemia-associated antigens (LAA).
Heterophile foetal antigen.
Foetal sulphoglycoprotein antigen (FSA).
b. with metabolic effects.
Placental alkaline phosphatase.
Placental-type hormones and related
products.
2. Present in tumours only.
The carcinoembryonic antigen (CEA)
Gold and Freedman (1965a) selected
colonic adenocarcinomata as source of
their human tumour antigen, hoping to
minimize the difficulties of previous in-
vestigators in obtaining an autologous
normal control tissue by employing normal
mucosa takeil at operation from a segment
of the colon distal to the tumour itself.
Rabbits were injected with pooled saline
extracts of the adenocarcinomata and the
resulting antisera, after absorption with
saline extracts of the corresponding
mucosa, human plasma, fibrin and killed
gut bacteria, were reacted with saline
tumour extracts to give a single line by
double diffusion methods. Extracts of
normal mucosa gave no reaction.
(a) Tissue distribution.-The distribu-
tion of the tumour antigen in a variety of
human tumours and normal tissues was
studied by the double diffusion precipitin
technique. Twelve colonic carcinomata
from different patients gave lines of com-
plete identity with each other. Other
tissues were tested and the tumour antigen
was found in primary alimentary tract
neoplasms from the oesophagus to the
rectum, including the pancreas, together
with their metastases. Primary tumours
at other sites, secondary tumours of the
alimentary tract and normal adult tissues
were all negative (Gold and Freedman,
1965b). However, the alimentary tract,
pancreas and liver of human foetuses aged
between 2 and 6 months contained small
amounts of an immunologically identical
substance which, definedbv these immuno-
logical tests, was called the " carcino-
embryonic antigen ".
Many further studies have now been
conducted confirming these original obser-
vations (von Kleist and Burtin, 1969a and
b) and extending them to show the exis-
tence of material probably identical with
CEA in some (Burtin et at., 1972) but not
all (Crichlow and White, 1970) colonic
polyps, some inflammatory gastrointesti-
nal and colonic disorders (Martin and
Martin, 1970) and in bronchial carcinoma
(Haverback and Dyce, 1972). With the
development of radioimmunoassays for its
measurement (Thomson et al., 1969),
CEA-reactive materials have been found
to be present in the serum of normal
healthy adults and in patients with a wide
variety of inflammatory or regenerative
disorders and benign and malignant neo-
plasms at many different sites (vide infra).
The faeces of healthy subjects and of
patients with colonic tumours also contain
CEA-like substances (Freed and Taylor,
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1972). In addition, the urine of patients
with urothelial carcinoma or urinary tract
infection containssubstance(s) which inter-
act with anti-CEA antibodies (Hall et al.,
1972).
(b) Properties. Gold and Freedman
(1965a) found that their antigen (CEA)
had an electrophoretic mobility in agar
gel similar to plasma fl-globulin and was
soluble in 0 6 mol/l perchloric acid, sug-
gesting that it was a mucoprotein. Subse-
quent studies have indeed shown that
CEA is a water-soluble glycoprotein,
consisting predominantly of carbohydrate
residues, including galactose, mannose,
glucose, fucose, glucosamine and avariable
amount of sialic acid (Krupey, Gold and
Freedman, 1967, 1968). The presence of
mannose and absence of N-acetyl-
galactosamine seem to distinguish it from
blood group substances.
The amino acid composition of CEA
was reported by Krupey et al. (1967, 1968)
and some of our own recent work has also
shown that the amino acids of blood
group substance H and CEA are different.
It is unlikelv that CEA is a single
homogeneous material. More than one
CEA peak has been eluted by gel filtration
(Coligan et al., 1972) or seen after ultra-
centrifugation (von Kleist and Burtin,
1969a).
In such sedimentation velocity experi-
ments with purified CEA, Krupey et al.
(1968) found a single peak with material
isolated from the hepatic metastasis of
a colonic tumour while a product from
a hepatocarcinoma gave 3 peaks. Von
Kleist and Burtin (1969a) and Coligan
et al. (1972) have observed 2 ultra-
centrifuge peaks with products derived
from colonic tumours. The faster sedi-
menting component may be a dimer of
the slower component (von Kleist and
Burtin, 1969a).
A number of authors have reported
the antigenic complexity of CEA. Gold
and Freedman (1965a) obtained 6 lines in
double diffusion between colonic tumour
extracts and antisera to colonic tumours
in rabbits incompletely tolerant to normal
mucosal extracts. Two of these lines
were also given by normal mucosa. Of
the remainder, 2 could be absorbed by
extracts of normal mucosa while the
other pair were both antigenically related
to CEA. As noted above, the CEA
isolated from a hepatoma which had 3
peaks in the ultracentrifuge (Krupey et al.,
1968) gave 2 lines against anti-CEA
antiserum.
Turner (1970) and his colleagues
(Turner, Kleinman and Harwell, 1970;
Kleinman, Harwell and Turner, 1971)
developed their own antisera in rabbits
against crude perchloric acid extracts of
colonic tumour proteins. The antisera,
after absorbing with human AB cells,
normal colonic mucosal extracts and
human serum, gave 2 lines against the
perchloric acid extracted colonic material.
It was not possible to separate either
antibodies or antigens responsible for the
2 precipitin lines, so they may have both
been related to CEA. It was found that
some of Gold's antisera also gave 2 lines
against the Kleinman et al. (1971) extracts.
We have injected 5 goats with lig
amounts of purified CEA according to the
prescription of Egan et al. (1972). One of
these goats developed 2 antibodies, one
reacting with CEA and another reacting
with a substance found in crude perchloric
acid extracts of colonic tumours (the
so-called X-substance). The relation of
" X" to CEA appears to be complex but
they may both share an antigenic deter-
minant.
(c) Metabolic significance.-Gold (Gold,
Gold and Freedman, 1968; Gold, Krupey
and Ansari, 1970) and von Kleist and
Burtin (1969a) found CEA to be localized
in the glycocalyx ofthe plasma membranes
of colonic tumour cells, and in particular
in that part of the membrane bordering
on the lumen of the neoplastic acini (von
Kleist and Burtin, 1969a).
Several studies have indicated that the
acquisition of a tumour antigen is accom-
panied by loss of normal cytoplasmic and
membrane antigens (Nairn et al., 1962;
Burtin, von Kleist and Sabine, 1971)
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which suggests that a precursor-product
relationship may exist between the tumour
and normal antigeins. Certainly, the area
of loss of normal antigens in a tumour,
using several sections, enclosed those
fields in which CEA was demonstrable
(Burtin et al., 1971).
The metabolism of the glycocalyx has
been studied by Gasic and Gasic (1962)
and Kraemer (1966), among others, who
found that the carbohydrate layer can be
replaced with a half-life of about one day.
If this is true for CEA, it would account
for its occurrence in plasma. Recent
experimental studies seem to corroborate
this view. Kim and Carruthers (1972)
examined 2 strains ofmammarycarcinoma
differing in metastasizing potential and
found an inverse relationship between
tumour content of a glycocalyx antigen,
not necessarily CEA, and its concentration
in the serum. Moreover, as the surface
glycoprotein declined in amount, the
metastasizing potential increased.
Another factor which determines the
plasma level of CEA may be its rate of
clearance. After complete resection of a
colonic tumour, plasma CEA levels fall to
a baseline level in a period that may be
between 2 and 18 days (Laurence t al.,
1972; LoGerfo et al., 1972b).
Much more information is required on
the detailed structure of the CEA mole-
cule, including the microheterogeneity of
its sugar units (Spiro, 1970), both between
molecules and within a single peptide
chain. The mannose and N-acetylglucos-
amine content of CEA relates the CEA
molecule to the core unit described by
Spiro (1970) as a common feature of
several glycoproteins linked to asparagine.
The absence of N-acetylgalactosamine
would suggest a lack of relationship with
the serine-linked glycoproteins which in-
clude the blood group glycoproteins.
The production of CEA is dependent
on the sequential action of a number of
glycosyl transferases. According to
Hakomori and Murakami (1968) the
tumour fails to complete its antigens, at
least those of a glycolipid nature. IfCEA
is anincompletenormal antigen,thenormal
product should be degradable to CEA.
This possibility must be borne in mind
when interpreting results on the distribu-
tion of CEA in tissues where autolysis or
chemical treatment could result in some
loss of terminal carbohydrate residues.
(d) Autoantibodies to CEA.- CEA is
highly immunogenic in the goat, as de-
monstrated by the low dose injection
schedules of Egan et al. (1972). Anti-
bodies against colonic antigens have been
detected in patients with colonic tumours
and with ulcerative colitis (Broberger and
Perlmann, 1959; von Kleist and Burtin,
1966; Gibbs and French, 1971). It would
therefore not be surprising if some ofthese
antibodies were directed against the CEA
molecule.
Gold (1967) found that 700% ofpatients
with localized cancer of the digestive
system had antibodies with haemag-
glutinating activity against human 0 cells
coated with CEA. The sera of 16 out of
20 women in the first and second tri-
mesters of pregnancy had haemaggluti-
nating activity. There was also activity
in postpartum maternal serum. Patients
with conditions other than colonic cancer
or pregnancy had no activity.
Results from other laboratories have
failed to find auto-antibodies to CEA.
Karitzky and Burtin (1]967) found that
the anti-colon antibodies in colonic cancer
patients reacted with antigens present in
the norinal colon. Collatz, von Kleist and
Burtin (1971) used the patients' auto-
antibodies to isolate the colonic antigens
with which they reacted. These antigens
were not CEA.
LoGerfo, Herter and Bennett (1972a)
searched for antibodies able to bind
labelled CEA in colonic tumour patients'
plasma. The mixture of CEA and plasma
was fractionated to identify CEA bound
to macromolecules but none could be
found. LoGerfo et al. (1972a) suggested
that the Gold (1967) reaction was possibly
due to blood group substances in his CEA
that he used to coat the red cells. This
explanation does not by itself account for
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the failure of' the clinical control groups to
show activitv in Gold's experiments.
The assay of Egan et al. (1972) is
potentially capable of registering CEA or
anti-CEA in the plasma as "immuno-
assayable CEA". We have found that
this assay separates certain WAest Indians
of African origin into 2 groups with high
(>20ng/ml) plasma CEA (7 individuals)
and normal (<10 ng/ml) CEA (3 indi-
viduals) (Laurence et al., 1972). The
high group all have anti-A isoantibodies
in their plasma whereas the low group
have no anti-A. No such effect can be
detected in Caucasians or in a small
number of Indians or Chinese.
There is no evidence that the high
values with Africans are directly due to
antibody binding; the anti-A activity may
be correlated with presence of cross-
reacting antigens in the plasma.
(e) The CEA tests.--Thomson et al.
(1969) developed a radioimmunoassay
which could detect 25 ng CEA/ml and
found that all except one of 36 patients
with active colonic or rectal cancer had
raised serum levels which became un-
detectable after successful surgery. Of
about 30 cases with digestive system
cancer at other parts ofthe tract, only one
(a disseminated pancreatic cancer) had a
high CEA level; tumours outside the
digestive system and non-neoplastic di-
seases also gave negative results.
Gold (1971) concluded that the CEA
test was virtually diagnostic of digestive
system cancer and with this specificity
and high positive rate was a suitable test
tor screening.
Other groups of workers interested in
the CEA concept developed radioimmuno-
assays (LoGerfo, Krupey and Hansen,
1971;Moore et al., 1971; Egan etal., 1972)
of which the methods of LoGerfo et al.
(1971) and Eganet al. (1972) have received
most study. We have compared both
methods, which employ different prepara-
tive methods and assay techniques. While
2*5ng/ml isthe upperlimitofnormalbyone
system (LoGerfo et al., 1971), the compar-
able level in our hands using the other is
12 5 ng/ml. This is due to the presence
of interfering background substances in
the unextracted plasma used in the latter
test system. We found that there was,
however, a high degree of qualitative
correlation between them (Laurence et al.,
1972). This is also substantiated by the
almost uniform agreement between differ-
ent groups as to the incidence of positive
and negative results in a wide variety of
disorders (Tables II and III).
The assay of plasma CEA seems to
have most clinical application in the
diagnosis of carcinoma of the gastro-
intestinal tract, pancreas and bronchus,
approximately 70-90%o of which will
yield raised levels (Table II). It is also
of value in the assessment of neuro-
blastomata (Reynoso et al., 1972; Table
III) and possibly testicular and mammary
neoplasms (Tables II and III). Unfor-
tunately, its estimation has little or no
part at present to play in the diagnosis
of tumours at other sites (Table III;
Laurence et al., 1972).
Neither the cell type nor the degree of
structural differentiation of mammary,
bronchial and gastro-intestinal carcino-
mata seem to influence the level of pla,sma
(CEA. Rather, the extent of tumour
spread seems to be the principal factor
(Laurence et al., 1972). This has been
corroborated by others and also seems to
be applicable to tumours at other sites
(Table IV).
It is possible to divide the plasma CEA
levels into 3 groups using the Egan et cl.
(1972) assay, namely normal (<12 5 ng/
ml), intermediate (12.5-40 ng/ml) and
high (>40 ng/ml). Patients with benign
and malignant tumours and with inflam-
matory or regenerative disorders may fall
into either the normal or intermediate
groups (Tables II and III); levels in excess
of 40 ng/ml are virtually diagnostic of
malignancy (Laurence et al., 1972). While
3000 of mammary, 45%o of colonic and
60% of bronchial carcinomata which are
still localized can give intermediate or
high values, only 8, 12 and 17% respec-
tively of such early tumours yield levels in
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TABLE II.-Plasma CEA Levels Using Different Methods in Gastro-intestinal,
Bronchial and Mammary Disorders
Disorder
Healthy controls
Carcinoma of
Colon and rectum
Pancreas
Liver
Other sites
Polyps of
Colon and rectum
Inflammatory/Reactive
Ulcerative colitis and
Crohn's disease
Diverticulitis, peptic
ulceration
Cirrhosis and alcoholic
liver disease
Alcoholic pancreatitis
Other
Carcinoma
Benign tumour
Reactive
Fibroadenosis
Carcinoma of
Bronchus
Upper respiratory tract
Inflammatory/Reactive
Pulmonary tuberculosis
Chronic bronchitis and
K emphysema
Incidence of positive plasma CEA assays
Zamchek LoGerfo Reynoso Laurence Total
et al., 1972 et al., 1972b* et al., 1972 et al., 1972 (% incidence)
0/40 0/100 1/138 0/57 1/335 (0.3%)
43/60
23/26
0/2
6/14
1/15
1/41
24/46t
17/32t
0/1
97/133
12/12
8/12
23/30
3/30
6/13
0/12
0/15
1/19
29/44
- 0/16
6/8 26/35
0/1
- 5/42
29/35 61/88 230/316 (73%)
3/3 10/11 48/52 (92%)
1/1 3/3 12/18 (67%)
8/11 14/30 51/85 (60%)
0/9 2/13 6/67 (9%)
13/41 20/95 (21%)
7/21 7/33 (21%)
4/5 28/66 (42%)
- - 17/32 (53%)
1/24 2/43 (5%)
16/35 37/74 82/159 (52%)
0/4 1/20 1/24 (4%)
5/54 5/70 (7%)
7/10 26/37 65/90 (72%)
8/14 8/15 (53%)
8/21 8/21 (38%)
11/21 16/63 (25%)
* See also Moore et al., 1971 and LoGerfo et al., 1971.
t Non-alcoholic liver and pancreatic diseases gave normal values.
TABLE III.-Plasma CEA Levels Using Different Methods in a Variety of
Different Neoplastic and Reactive Disorders
Disorder
Incidence of raised plasma CEA assays
Zamchek LoGerfo Reynoso Laurence Total
etal., 1972 et al., 1972 et al., 1972 etal., 1972 (% incidence)
rCarcinoma of
Uterus Cervix
Endometrium
O Carcinoma
Ovary 0 Benign tumours
Seminoma
Testis Teratocarcinoma
Other
Prostate Carcinoma
Reactive hypertrophy
Kidney rCarcinoma KRenal failure
Bladder Carcinoma
rNeuroblastoma
Nervous system Intracerebral
malignant tumours
Haematological Lymphoma
6/12
3/6 7/19
2/4
4/10 1/5
4/9
6/12
1/3
25/52 8/32
0/17 1/11
218 4/7
0/13
6/12 11/45
6/6
0/2 2/18
9/20
1/7
2/5
0/2
1/1
5/7
4/9
1/2
3/11
18/49
2/7
19/45 (42%)
3/11 (27%)
7/20 (35%)
0/2 (O%)
5/10 (50%)
11/19 (58%)
1/3 (33%)
37/93 (40%)
2/30 (7%)
9/26 (35%)
6/25 (24%)
34/106 (33%)
6/6 (100%)
2/7 (29%)
2/20 4/7 6/27 (22%)
1/7 11/29 14/56 (25%)
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TABLE IV.-Influence ofStage of Tumour Progression on the Plasma CEA Levels
Carcinoma of
Colon and rectum
Bronchus
Breast
Prostate
Bladder
Cervix
Stage
Dukes A
Dukes B
* Dukes C
Metastasized
Local NO, MO
LocalN+,MO
Metastases
Local NO, MO
. Local N+, MO
Metastases
Local
* Metastases
Local
Metastases
Stage 0
9 Stage I
* Stage 2
tStage 3
* LoGerfo et al., 1972b.
the " cancer " diagnostic range (>40 ng/
ml). Hence, when it is appreciated that
each of these cases was a clinically overt
neoplasm, the detection rate of even
earlier lesions may be less. Thus, at
present estimation of plasma CEA levels
does not appear to be a worthwhile screen-
ing procedure. However, we are unable
to state that by detecting a group of
subjects with raised plasma CEA levels
and then investigating them in detail,
lives would not be saved. In fact, some
patients have had high CEA levels before
overt neoplasia develops (Stillman and
Zamchek, 1970).
Disorders such as diverticulitis, peptic
ulceration, ulcerative colitis and Crohn's
disease, which feature prominently in the
differential diagnosis of gastrointestinal
neoplasia, can give CEA levels in the
intermediate (12-5-40 ng/ml) range (Table
II; Laurence et al., 1972). Detectable
carcinomata were not found in any of the
subjects in our series, and with ulcerative
colitis and Crohn's disease there did not
appear to be any correlation with the
disease severity. Consequently, CEA has
little value, if any, in the differential
diagnosis of gastro-intestinal neoplasia.
Similar conclusions may be drawn for
pulmonary disease. The highest inci-
dence of " false positive values " occurs in
patients with chronic bronchitis and
emphysema and those who also smoke
cigarettes, the very group in which it
would have been valuable to use the test
to screen for bronchial neoplasia. How-
ever, it may be premature to dismiss the
raised values in patients with other
disorders as " false positives " in view of
the observations of Stillman and Zamchek
(1970).
The most valuable aspect of the CEA
test at present would appear to be as an
adjunct to monitor therapy and to detect
residual disease and the development of
metastases. If the plasma CEA is raised
pre-operatively, it declines to normal
between the second and the eighteenth
post-operative day, if the tumour has
been completely removed. A remaining
high level indicates residual disease. From
limited experience, the levels almost
always rise again with the development of
metastases (Table IV\; Laurence et al.,
1972), and it would appear worth while
now to assay CEA pre-operatively and
during the post-operative phase and at
each out-patient attendance, to ascertain
if the presence of recurrent or residual
disease may be detected earlier. Whether
this will affect the long-term survival or
prognosis remains to be determined.
The estimation of CEA in urine in
Reynoso
et al., 1972
7/19*
14/23*
21/28*
46/54*
1/10}
15/25
4/24
4/8
9/35
2/11
0/4
2/5
3/5
2/5
Laurence
et al., 1972
13/29
22/29
6/10
20/20
15/24
5/6
6/7
12/39
9/20
6/7
1/4
3/5
13/34
6/13
1/3
3/9
2/4
3/4
Total
(% incidence)
20/48 (42%)
36/52 (69%)
27/38 (71%)
66/74 (89%)
15/24 (63%)
5/6 (83%)
6/7 (86%)
22/69 (32%)
21/32 (66%)
5/28 (18%)
7/13 (54%)
22/69 (32%)
8/24 (33%)
1/7 (14%)
5/14 (36%)
5/9 (55%)
5/9 (55%)
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patients with bladder carcinomata has
also clinical and diagnostic significance.
High levels of CEA-like materials can be
detected in approximately 7000 ofpatients
with bladder tumours and even in those
with early in situ lesions. Patients with
urinary infection, however, may give
falsely elevated levels which can also arise
from contamination with vaginal or cer-
vical secretions (Hall et al., 1972).
Successful removal of the bladder
tumour is associated with a decline to
normal levels. Of interest is that hyper-
nephromata and other non-urothelial
tumours do not cause a raised urinary
CEA level even in the presence of high
plasma levels, except when such tumours
invade the urothelial passage.
The alpha-foetoprotein (AFT)
In 1963, Abelev et al. developed
antisera against the serum proteins of
newborn mice and absorbed them with
adult mouse serum. The resulting ab-
sorbed antisera reacted not only with a
component of newborn mouse serum but
also with the sera of adult mice carrying
a transplantable hepatoma. The foetal
serum protein, which had the mobility of
an al-globulin, was also detected in the
blood of adult mice after partial hepatec-
tomy and of adult mice carrying 2 other
transplantable hepatomata. No antigen
was present in the serum of mice with
transplantable tumours other than hepa-
tomata.
Tatarinov (1965) observed reaction
between an antigen in the blood of 2
patients with primary carcinoma of the
liver and the monospecific antiserum
against afoetal component ofhumanblood.
Other workers (Kithier, Masopust and
Radl, 1968; Terent'ev, 1969) have shown
that foetal calf serum contains several
distinct foetal proteins, one of which is
fetuin, which is not increased in cows with
hepatocellular carcinoma whereas a second
xl-globulin component is elevated. The
occurrence of a distinct protein species
that is predominant in early foetal serum
and also hepatoma-related has been estab-
lished in 18 mammalian species by
immunological cross reactions (Gitlin and
Boesmann, 1967a). This component is
now given the general name, alpha-foeto-
protein (AFP).
(a) Tissue distribution.-Studies on the
distribution ofAFP have been conditioned
by the detection method. In early foetal
serum and in the serum of certain patients
with hepatomata, the protein band is
easily visualized by zone electrophoresis
which can detect 300pig/ml AFP in serum.
Double diffusion, which has been the
principal detection method until 1970,
has a sensitivity of 1-3 pug/ml. More
recently (Abelev et al., 1971) aggregate-
haemagglutination and immunoautoradio-
graphy have detected 50 ng/ml while
radioimmunoassay can respond to 0-25
ng/ml (Ruoslahti and Seppala, 1971).
With development of more sensitive
methods, the somewhat capricious differ-
ences found in early work, e.g. between
mice and rats or between Caucasians and
Africans, have been shown to be quantita-
tive rather than qualitative in nature.
AFP is the major protein component in
the serum ofearly rodent (Pantelouris and
Hale, 1962; Kirsh, Wise and Oliver,
1967) and human foetuses; the highest
level in the human foetus is of the order
of 3-4 mg/ml serum (Gitlin and Boesman,
1966) and is attained around the thir-
teenth week of intrauterine development,
having been detected by double diffusion
technique from approximately the sixth
week. With increasing foetal age, AFP
levels decline and albumin concentrations
rise, and by the end of the first post-natal
week, AFP is no longer demonstrable.
The transition between AFP and albumin,
as the predominiant foetal serum protein,
occurs somewhat later in relation to
gestational age in rodents than in man.
The cut-off point atwhich AFP is no longer
detectable by double diffusion methods is
also later in rodents (Tatarinov, 1965).
However, the use of sensitive radio-
immunoassay has shown that small
amounts (4-25 ng/ml) persist in normal
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adult serum (Ruoslahti and Seppala,
1971). In addition, trace amounts are
detected in cord blood and in the amniotic
fluid (von Kleist et al., 1968). Recent
results have also shown that the AFP
content of sera of pregnant women
departs from the normal value (Abelev
et al., 1971; Seppala and Ruoslahti,
1972a). During the first, second and
third trimesters, the maternal serum
levels vary between 18 and 119 ng/ml,
96 and 302 ng/ml and 103 and 550 ng/ml
respectively, dropping shortly before term
to normal. Levels in excess of 1000 ng/ml
occur before and after foetal death, and it
has been postulated that an increased
release ofAFP may occurbecause offoetal
distress (Seppala and Ruoslahti, 1972b).
AFP is formed principally by the
rodent and human foetal liver, but also
by the yolk sac and gastro-intestinal tract
(Gitlin and Boesman, 1967b; Engelhardt
et al., 1969; Gitlin and Pericelli, 1970;
Gitlin, 1971). Other foetal tissues, in-
cluding spleen, lung and kidnev, the
placenta and adult liver do not appear
to form AFP in significant amounts
(Wise and Oliver, 1966; Abelev and
Bakirov, 1967). Offurther interest are the
reports which showed that its major
synthetic site in sharks is the gastro-
intestinal tract and, in birds, the yolk sac
(e.g., Gitlin, 1971).
In the liver, most hepatocytes are
initially involved in AFP synthesis by the
sixth week of foetal life, but as the serum
levels commence to fall the numbers of
cells staining immunofluorescently decline
also and tend to be those situated around
the central vein. The Kupffer cells, bile
duct epithelium and haemopoietic cells
do not appear to synthesize AFP at any
time (Engelhardt et al., 1969).
In regenerating liver (Engelhardt et al.,
1969) and also in hepatoma (Gusev et al.,
1971) only certain cells in the tissue give
an AFP reaction by immunofluorescence.
The " positive " hepatoma cells were
more frequently adjacent to the tumour
vessels, suggesting that production of
AFP is not entirely a random process.
Nishioka et al. (1972) have observed that
less than 20% of the cells of a hepatoma
contained AFP. The AFP-containing
cells had larger, more hyperchromic nuclei
than the AFP negative cells.
(b) Propertie8. AFP belongs to a
class ofproteins widely distributed among
mammalian species (Gitlin and Boesman,
1967a; Masopust, Zizkovsky and Kithier,
1971). AFP of human origin is an
ac,-globulin with a molecular weight of
64,000 and a sedimentation constant of
4-5 (Nishi, 1970). Approximately 40o
of the total protein is carbohydrate
(Ruoslahti et al., 1971). Hexose, hexos-
amine and sialic acid occur in it in a ratio
of 2-2: 1-2: 0 9 by weight. While sam-
ples of the proteins from foetal sources
show uniform electrophoretic mobilities
those of tumour origin have up to 4
variants or sub-components with slightly
different mobilities (Purves, Van de Merwe
and Bersohn, 1970a). By treating with
neuroaminidase and removing the sialic
acid from the carbohydrate component
of the protein, these differences between
the variant tumour products are removed
so that such differences between products
are probably related to variations in the
carbohydrate rather than the peptide
changes.
Nishi (1970) and Ruoslahti and his
colleagues (1971) have determined the
amino acid composition of AFP after
purification using immunological methods.
The results ofthe 2 groups agree very well.
Each finds that AFP isolated from foetal
serum and from serum of a hepatoma
patient have very similar total amino acid
compositions. The latter group have also
found identical peptide maps for tumour
and foetal AFP.
Abelev (1971) has emphasized the
similarity in chemical and physical pro-
perties of albumin and AFP, which makes
separation by other than immunological
methods difficult. The amino acid com-
positions of AFP and albumin are very
similar. However, the content of glycine
and of isoleucine in human albumin is
about half and one-third respectively that
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ofAFP. The serine andthreonine content
of AFP is about 50% higher than in
albumin. Both AFP and albumin have a
high leucine content (about 10% of all
amino acid residues). Like albumin, AFP
can bind oestrogens but AFP cannot bind
testosterone (Uriel, de Nechaud and
Dupiers, 1972), though this steroid is
strongly bound to albumin.
AFP is clearly distinct from fetuin in
its carbohydrate-fetuin has 20% carbo-
hydrate-and amino acid composition
(Spiro, 1960). Their solubility character-
istics and immunological properties are
also widely different (Bergmann, Levine
and Spiro, 1962; Kithier et al., 1968
Terent'ev, 1969).
Metabolic signifcance
The role played by AFP in foetal life is
not clear; it appears to be a substitute for
albumin of the adult serum. As some
adult individuals lacking serum albumin
(Bennhold and Kallee, 1959) seem to be
able to live without gross metabolic
defects, the similarity of albumin to AFP
does nothelptodetermine thetruefunction
of the latter. Certainly, albumin plays
animportantpartincontrollinghaemolytic
jaundice of the newborn (Bennhold, 1962)
and a similar " emergency overflow "
mechanism may operate for AFP in the
foetus. AFP is known to bind oestrogens
(Uriel et al., 1972).
The recent development of radio-
immunoassay techniques for AFP resulted
in its demonstration in the serum of
healthy adults so that, like CEA, there
does not appear to be complete gene
suppression as was originally considered
from the data of less sensitive methods.
Hence, reappearance of AFP in liver
diseases of the infant (Masopust et al.
1968, 1971) and adult associated with
inflammation and/or regeneration (Abelev
et al., 1963; Table V; Abelev, 1971) is not
unexpected. However, the explanation
is not a simple one. Abelev et al. (1967)
pointed out that when AFP levels are
falling in late gestation, the liver is still
undergoing very rapid proliferation, and
that this rapid growth continues into early
childhood when no AFP can be found in
the serum by gel diffusion.
In experimental animals, acute poison-
ing with carbon tetrachloride leads to a
rise in AFP level; a peak develops at 2-3
days after exposure, declining thereafter
and becoming negative 8-10 days later
TABLE V. Serum AFP Assay Results by Gel Diffusion Methods
Incidence of positive serum
AFP assays
Site Disorders Number %
Normal controls 0/15,730 (0)
Pregnancy * 13/1069 (1-2)
FHepatocarcinoma 589/868 (68)
Liver . Cholangiocarcinoma 1/73 (1.4)
Non-neoplastic* 15/6484 (0.2)
TTeratocarcinoma . 49/108 (45)
Seminoma 0/39 (0) Gonad Choriocarcinoma 2/15 (13)
LOther tumours 0/13 (0)
Kidney Nephroblastoma . 0/59 (0)
Neurobla,stoma 0/70 (0)
Non-hepatic primary malignant 10/1169 (0 8)
tumourst
Miscellaneous+ 1/3373 (0.03)
* Twelve of the positive assays had either viral hepatitis or cirrhosis.
t All 10 positive assays were in patients with hepatic metastases.
. The positive is an example of hepatoblastoma.
From the data reviewed by Abelev, 1971; Masopust et al., 1971; Kozower et al., 1971; Mehlman et al.,
1971; Alpert et al., 1971.
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(Bakirov, 1968; Perova, Elgort andAbelev,
1971). The experiment may then be
repeated on the same animals with similar
results.
Hepatomata induced in rats by a
variety of carcinogens gave different
incidences of raised serum AFP levels
(Stanislawski-Birencwajg, 1967) depend-
ing on the inducing agent and the manner
of its application. However, aflatoxin-
induced tumours were consistently nega-
tive.
While Abelev et al. (1967) have found
a correlation between AFP levels and the
time required for transplantable hepato-
mata to kill the host animal, no such
correlation has been found for tumour
subjects though Purves, Bersohn and
Geddes (1970b) found lower serum levels
in patients with the more differentiated
tumours.
There is a wide range of AFP levels in
patients with hepatomata. Although the
total range between patients is 500,000-
fold, the variation for a given patient is
rarely more than 10-fold over the time of
observation (Purves et al., 1970b). As the
outcome of the disease does not appear to
differ depending on the AFP level, this
suggests that there is a homoeostatic
control mechanism for AFP production in
the tumour cells. This does not seem to
be true for teratocarcinomata (Mawas et
al., 1971).
The time course of AFP production is
little understood. Hull et al. (1969) have
shown that AFP production can precede
the development of nitrosodiethylamine-
induced hepatomata in monkeys. In
others there is no apparent AFP produc-
tion. Such tumours possess a prominent
lymphocytic infiltrate, which disappears
if and when these lesions start to form
AFP. Kroes and Weisburger (1972)
observed a burst of AFP production in
rats 3-5 weeks after administering 3-
methyl DAB together with aflatoxin.
The AFP level returned to normal until the
tumour developed, when a second increase
in serum AFP concentration occurred.
At a cellular level, the presence of
AFP in only a few of the tumour cells
suggests that AFP production is an
activity of a minority of the cell popula-
tion. An alternative interpretation would
be that all the cells are making AFP but
few are storing the protein. If the AFP-
producing cells are associated with the
vessels as suggested by Gusev et al. (1971)
then AFP production or the location of
AFP cells must be subject to physiological
gradients.
The presence of AFP in normal adults
means that some cells, not visualized by
immunofluorescence, continue to produce
AFP throughout life. Either these are
very few cells working at normal rate or a
larger number of cells that are modulated
to a subnormal rate. Restoration of AFP
production would then be by proliferation
of a very small number of cells, remodula-
tion to a higher level of production, or
perhaps both.
At a molecular level, the genetic
information required to make the peptide
portion of AFP would be expected to be
present in the genome of adult cells.
Expression of the genetic information
would require a lifting of repression at the
gene level, possibly together with the
development of protein synthetic appara-
tus and the multiplication of committed
cells. The synthesis and control of the
carbohydrate chains of AFP, which are
apparently the source of variation in the
molecule (Purves et al., 1970a), would be
dependent less directly upon information
in the genome. Like CEA, these carbo-
hydrate chains are the result of sequential
action of sugar transferases at appropriate
cell loci. The variant chains could be the
result of differences in relative concentra-
tions and location of these enzymes in the
cytoplasm.
(d) The AFP tests. The history of the
several AFP tests introduced during the
past few years is one of progressive
improvement in sensitivity over a 1000-
fold range. The double diffusion tech-
nique, which was the most sensitive
method up until 1970 and was capable of
measuring I Itg AFP/ml serum, introduced
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a somewhat arbitrary cut-off value as
normal serum levels of AFP remained
undetectable (Abelev, 1971), until the
more sensitive methods became available.
By the gel diffusion method, however,
the AFP test is remarkably specific for
hepatocellular cancer and teratocarci-
noma, as is shown in Table V, where most
of the reported data have been collated.
These are the types of results which could
be expected by using the several com-
mercially available AFP diagnostic gel
diffusion kits. It would appear that non-
hepatic primary neoplasms only result in
raised serum AFP levels by this method
once they have metastasized to liver.
This has been shown for pancreatic, gastric
and prostatic carcinomata (O'Conor et al.,
1970; Alpert, Pinn and Isselbacher, 1971;
Kozower et al., 1971; Mehlman, Bulkley
and Wiernik, 1971).
At the level of sensitivity of the gel
diffusion technique, over 50%o of hepato-
mata can be detected in those areas of the
world where the disease is most common
(Abelev, 1971). Among Caucasians the
percentage detection is considerably lower
(Table VI). However, analysis of these
TABLE VI.-Serum AFP Assay Results in
Hepatocarcinoma by Gel Diffusion
Methods as a Function of Country of
Origin*
Hepatocarc inoma
in
Russia
Europe
U.S.A. fCaucasian Negro.
Africa
Far East .
Incidence (%)
77
41
31
71
78
6S
* From data reviewed by Abelev (1971).
data and their division into different age
groups revealed that all patients with
hepatocarcinomata between 10 and 30
years had elevated AFP levels by gel
diffusion. Only 66% and 22% of subjects
between 31 and 40 years and over 40 years
respectively with hepatoma had raised
levels. This may partly explain the
different continental incidences as Africans
tend to develop the disease 2-3 decades
earlier.
Increasing sensitivity, by using an
immunoautoradiographic method with a
lower limit of detection of 50 ng/ml,
results in an increased incidence of detec-
tion of hepatoma, and in particular there
is a greater increase in positive results with
Caucasians than with other races whose
incidence by the gel method is already
high (Table VI; Abelev et al., 1971). In
addition, approximately 7500 of patients
with teratocarcinomata have raised
values whereas seminomata still yield
negative results (Abelev et al., 1971). At
this level of detection, the majority of
women after the sixteenth week of preg-
nancy and 1300 of patients with infective
hepatitis have a positive AFP test.
Thus, the previous specificity is lost with
increasing sensitivity.
Radioimmunoassays are capable of
detecting AFP in the blood of normal
individuals and also assign numerical
values to theresults from cases that cannot
be quantitated by the other methods.
Even with the most sensitive methods
about 5-1000 of cases of patients with
hepatomata still have AFP levels within
the normal range.
The actual level of AFP seems to
remain remarkably steady in any one
person and appears to be independent
of tumour size, stage or differentiation
(Purves, Macnab and Bersohn, 1968).
This was also noted in association with
some experimental hepatomata. Success-
ful therapy, including chemotherapy, is
associated with a decline in serum levels,
which rise again with relapse to reach the
same or higher level.
Houstek and his colleagues (1968)
believe that AFP tests are as good as, and
probably safer than, percutaneous biopsy.
There is evidence from the experimental
production of hepatomata in monkeys
that AFP serum levels may be elevated
before tumours develop. This may also
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be so for man (Hull et al., 1969); one
patientwith cirrhosis originally had normal
AFP levels which became positive by gel
diffusion 7 months before an hepatoma
was discovered (Khasanov et al., 1971).
A test for AFP is also valuable in the
differential diagnosis of teratoma and
seminoma (Table V) and in following the
course ofthe former in response totherapy.
Mawas et al. (1971) have observed that
patients with raised AFP levels have
more malignant teratomata, while the
majority of AFP negative malignant
teratomata respond to therapy.
Mention has already been made of the
increasing serum AFP levels in maternal
serum and the further rises which develop
inl association with foetal distress.
Too few results have been published
at this time to enable the value of radio-
immunoassay for AFP to be assessed fully.
As with those for CEA, some degree of
non-specificity will almost certainly be
observed with more sensitive methods,
but it would seem that AFP assay is of
value in the detection, differential diag-
nosis and therapeutic monitoring of
patienits with hepatocarcinoma and terato-
carcinoma, and in addition with other
tumours to ascertain if and when hepatic
metastases develop. Finally, it would
seem to serve as a possible index of foetal
well-being.
x2H-Foetoprotein (c2HF)
Significantly less information is known
about this macromolecule. ac2H-Foeto-
protein is detected in foetal liver and
serum and in serum up to the end of the
second post-natal month (Buffe et al.,
1970). It is a 17 S iron-containing macro-
globulin and, using radioimmunodiffusion,
it is possible to measure 1 5 ng/ml serum
(Buff6 et al., 1970).
Elevated serum values occur in adults
with various tumours, including hepatoma,
cholangiocarcinoma and lymphoma. Most
experience has been gained with paediatric
tumours occurring after the age of 3
months (Table VII). W"hile there does not
appear to be any correlation within
TABLE VlII. Serum x2 H-Foetoprotein in
Various Disorders*
Incidence of
positive serum
Disorder assays
Nephroblastoma 24/27
Neuroblastoma . 20/26
Teratoma 14/20
Hepatoma 19/29
Cholangiocarcinoma 2/5
Myeloma 46/145
Lymphoma 26/62
Leukaemia acute ?8/85
-chronic 1/25
Cerebral tumours 15/18
Cirrhosis 19/48
Controls . 3/55
* Data from Buffe et al., 1970; -Martin et al., 1971;
Wada et al., 1971.
tumour groups with respect to site or cell
type (Martin, Charlionet and Ropartz,
1971), there is a relationship between the
rate of evolution of the tumour and the
presence of serum x2HF. Raised levels
are uncommon in children with non-
cancerous conditions. Occasional healthy
adult subjects have detectable serum
levels, which are also seen in association
with regeneration and/or inflammatory
liver diseases.
Much remains to be done to achieve a
better knowledge of its occurrence and
more sensitive methods of detection are
needed. It is, for example, not known if
a2HF levels decline in serum with success-
ful therapy, although they are known to
rise before or with a recurrence of disease
(Buff6 et al., 1970).
/lS-Foetoprotein
Takahashi and his colleagues (1967)
described /JS-foetoprotein which occurs in
elevated amounts in the serum of patients
with hepatocarcinoma (10/23), cholangio-
carcinoma (1/5), gastric carcinoma (2/7)
and leukaemia and lymphoma (2/7) (Wada
et al., 1971). As with the other foetal
antigens, raised serum values can also be
detected in liver diseases such as cirrhosis.
Double diffusion agar methods and
immunoelectrophoresis have been used to
demonstrate this foetoproteinwhich occurs
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in foetal serum and tissues, including the
liver, disappearing from the body fluids by
the fifth-seventh post-natal month. Pre-
liminary studies have shown that it is a
glycoprotein whose molecular weight prob-
ably exceeds 200,000. In contrast to CEA,
it is located in the cytoplasm of foetal
hepatocytes. The behaviour of this
material in response to anti-tumour
therapy has not been reported.
Leukaemia-associated antigens (LAA)
Within embryonic tissues and serum
are macromolecules that are also present
in the serum of approximately one-third
ofpatients with various types ofleukaemia
(Harris et al., 1971). These leukaemia-
associated antigens (LAA) seem to be
derived from the tumour cell membrane
and are also present in the sera of some
patients with Hodgkin's disease. Using
double diffusion and cross-over electro-
phoretic methods, LAA are not seen in the
sera of normal persons or of patients with
hepatomata. Unfortunately, serum LAA
levels need not decline during remission.
Further studies are required to outline the
value of these materials in the clinical
management of leukaemia.
Heterophilefoetal antigen
Edynak and his associates (1970) have
reported a heterophile antigen in foetal
but not neonatal or adult sera, except for
the sera of 17 of 200 patients with various
tumours, including leukaemia. This
material is capable ofeliciting an antibody
response in about 1% of patients with
various types of cancer and this antibody
can precipitate saline extracts of many
diverse types ofhuman tumours, including
those arising from breast, colon, ovary,
kidney, muscle and bone.
While the antigen does not occur in
the serum of healthy persons, it can be
detected in some simple tumours and
some non-neoplastic tissues. It has the
electrophoretic mobility of a y-globulin
and it has been suggested that it and the
LAA may be related (Alexander, 1972).
To date, the effects of therapy upon its
levels are unknown; if more sensitive
techniques do not become available, its
low incidence in neoplasia makes it
unlikely to have clinical usage.
Foetal sulphoglycoprotein antigen (FSA)
Three sulphoglycoproteins are known
to appear in the human foetal gastro-
intestinal tract about the seventh or
eighth week of intrauterine development
(Hakkinen, Korhonen and Saxen, 1968).
One of them, located in the cells of the
superficial epithelium of the foetal
stomach, disappears from this site 9
months after birth and is called foetal
sulphoglycoprotein antigen (FSA).
Hakkinen and Viikari (1969) reported
that 96% of patients with gastric carcino-
mata contain FSA in the gastric juice.
Immunological studies showed that FSA
was present in the tumour cells and in the
superficial cells of the mucosa in relation
to the tumours (Hakkinen, Jarvi and
Gironroos, 1968). It was also found,
using double diffusion methods at this
site, in 14% of subjects with peptic
ulceration and in some patients with non-
epithelial neoplasms. FSA production
was also noted to apparently precede the
development of overt gastric carcinoma.
Wrhile this is a most interesting and
important observation, the incidence of
FSA-positive patients with peptic ulcera-
tion far exceeds their known incidence of
malignant change of approximately 2%.
Further chemical and immunological
studies ofthis material and its relationship
to intestinal metaplasia are needed. Un-
fortunately, successful removal ofa gastric
tumour need not be followed by a decline
of FSA levels in gastric juice.
Carcinoplacental alkaline phosphatase
The induction of experimental neo-
plasia is frequently associated with the
activation of isozymes characteristic of
foetal or neonatal organs. Generally,
there is a quantitative change toward the
foetal pattern, e.g. lactate dehydrogenase,
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aldolase (Leese, 1969). While these
observations have important basic conno-
tations in the field of differentiation, of
great clinical importance are qualitative
isozymic alterations which are also
reflected in the body fluids. To date, the
only isozyme fitting the latter category is
the placental alkaline phosphatase.
At least 5 organ-specific isozymes of
alkaline phosphatase are known to occur
in the serum and are derived from the
liver, bones, lung, intestinal tract and
placenta. The placental isozyme does
not occur in foetal tissues or serum but is
present in maternal serum during the third
trimester of pregnancy. It is charac-
terized by being heat stable and inhibited
by L-phenylalanine, in contrast to the
other forms (Fishman et al., 1968), and is
never found in the serum of normal male
subjects.
The isozyme, first detected in a
patient named Regan with bronchial
carcinoma, occurs in the serum of a
minority of patients with a wide variety
of neoplasms (Table VIII). In addition,
many of the important pre-cancerous
disorders or diseases which feature in the
differential diagnosis of neoplasia can
result in " false positive " results (Table
VIII).
TABLE VIII.-Incidence of Regan Isozyme
of Alkaline Phosphatase in the Sera of
Patients with a Variety of Disorderst
Disorder
Bronchial carcinoma
Mammary carcinoma
Genito-urinary carcinoma
Lymphoma.
Malignant melanoma
Gastro-intestinal carcinoma
Alcoholic cirrhosis*
Hepatitis*
Ulcerative colitis*
Diverticulitis*
Hydronephrosis*
Incidence of Regan
isozyme
7/51
6/49
10/55
2/25
0/5
10/81
2/8
0/6
2/4
1/1
1/2
* From Nathanson and Fishman, 1971.
t These patients form a selected rather than a
random group of controls as each was found to have
a raised serum alkaline phosphatase level by routine
testing. The presence or absence of the Regan
isozyme was then sought.
25
This tumour-produced isozyme has the
same immunological, electrophoretic and
biochemical properties as the placental
isozyme (Nathanson and Fishman, 1971)
and has also been shown to beaproductof
Hela cells (Griffin, Cox and Grujic, 1967).
When present, this isozyme is clinically
useful to monitor tumour progression or
regression with therapy and can also be
detected in malignant serosal exudates.
It would seem that all patients with
unexplained raised serum alkaline phos-
phatase levels determined by the routine
methods should have the serum
reexamined to determine if the placental
isozyme is responsible for the aberrations.
A positive result would necessitatedetailed
clinical examination to detect or exclude
a latent neoplasm.
A variant of this carcinoplacental
alkaline phosphatase isozyme has been
detected by Warnock and Reesman (1969).
It occurs in the serum of some patients
with hepatoma but not cholangiocarci-
noma and/or liver damage, but only when
AFP levels are also raised (Portugal,
Azevedo and Manso, 1970). This isozyme
is different from the typical liver alkaline
phosphatase and is not produced by the
foetal liver.
Hormones
The ectopic hormone syndromes
represent a vast and important aspect of
oncology which is outside the scope of
this present article. They have been
recognized with increasing frequency in
recent years, and Ellison and Neville
(1972) consider ectopic hormone produc-
tion to be a disorder due to non-random
change in gene expression, and believe
that this mechanism also accounts for
foetal antigen production. This thesis is
given added credence when it is appre-
ciated that non-trophoblast containing
tumours can form substances usually of
placental origin. These include gonado-
trophins (Castleman, Scully and McNeely,
1972), human placental lactogen (HPL)
(Weintraub and Rosen, 1971) and plasmi-
nogen activators (Davidson et al., 1969).
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Bronchial tumours are most frequently
implicated but HPL has also been noted to
be a product of hepatoma and hepato-
blastoma (Weintraub and Rosen, 1971),
both of which also can produce AFP
(Table V).
Inappropriate hormone production
also serves as an index of tumour activity
and the levels decline with successful
therapy. It would seem worthwhile to
consider including a battery of hormonal
immunoassays in all assessments of the
functional activity of tumours.
Foetal macromolecules present only in
tumours
Many different human tumours have
been found to contain foetal antigens,
which to date have not been shown to pass
from the tumours into the body fluids.
Klavins and his colleagues (1971) have
declared that immunologically definable
embryonic cell components are present in
all human carcinomata. In favour of
this concept, which has support in the
field of experimental neoplasia (Stonehill
and Bendich, 1970), they were able to
demonstrate that absorbed anti-sera raised
against whole human 6-7 week old
embryos cross-reacted with extracts of
lung, breast, colonic, hepatic, renal, bron-
chial and skin carcinomata. No reactions
were observed with normal tissues except
the epidermis. In keeping with the hypo-
thesis that these manifestations are ex-
amples of retrogenetic expression, it has
been noted that the foetal and tumour
materials exhibit immunological identity
and have similar gel filtration properties
giving a molecular weight of the order of
66-68,000 (Klavins et al., 1971).
Two large macromolecular complexes,
one ofwhich is also present in foetal tissue,
have been isolated by Yashi et al. (1968)
from bronchial, gastric, pancreatic, renal
and hepatic carcinomata. Other gastric
and colonic carcinomata were shown to
have different but related antigens. These
molecules, despite diligent search, do not
occur in the body fluids. They are
insoluble in perchloric acid, although they
show slight staining with periodic acid-
Schiff's reagents, and are heat labile and
alcohol insoluble.
The presence of antigens common to
foetal tissues and tumours, including
those of colonic, mammary and pan-
creatic origin, has also been recorded by
Tee and his colleagues (Tee et al., 1965;
Barnes and Tee, 1971). In addition, 2
non-foetal antigens were demonstrated
by them in those tumours. Trouillas
(1971) found that glioblastoma and astro-
cytoma contain foetal brain macromole-
cules which are soluble in saline and
appear to contain lipid.
The discovery of each of these macro-
molecules, although of no immediate
practical clinical application, is of great
interest and importance. However, it
seems to us essential that theirrelationship
to one another and to the other ones
previously described should be ascertained
in the near future. Moreover, their
chemical nature and site in or on tumour
cells require clarification.
PROSPECTS
In this review, we have been dis-
cussing those presently known foetal
antigens which occur in association with
human neoplasia. Almost certainly the
next few years will prove that the list is
far from complete. It seems imperative
to us that if confusion of terminology and
duplication of research effort is to be
avoided, a co-ordinated scheme for distri-
buting material to interested workers
should be established within the near
future. In this way, new materials will
be assessed quickly, their relationship to
others outlined and their place in clinical
practice examined in an integrated and
detailed manner.
Another collaborative project would
be to define the specificities of the anti-
bodies used in reactions to detect and
evaluate the foetal antigens. The gel
diffusion method contains certain inbuilt
safeguards against the possibility that
more than one antigen will be included in
the evaluation of a given case. With
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radioimmunoassay, it may be difficult to
distinguish between ahighly activeantigen
present in nanogram amounts and a
second cross-reacting antigen with a con-
centration a thousand times greater.
A third study might consider whether
the concept of purity as normally under-
stood with chemical products is meaning-
ful in the field of carbohydrate-tumour
antigens. It is known, for example, that
tumour surface antigens differ from the
normal in part by their distribution and
availability, as defined by steric properties
of the cell surface. A similar steric
relationship may occur at a molecular level
in determining accessibility of groupings
on the antigen to antibody molecules.
It will be of interest to know if these
antigens have any role to play inindicating
tumour aetiology. Human tumours, like
animal tumours, seem to possess antigens
peculiar to one tumour or common to
different tumours of similar or differing
histology and at various sites. The evi-
dence from experimental animal studies
that shared antigens may be indicative of
similar aetiology, such as a virus, has
profound meaning for human neoplasia.
The field ofhistopathology may benefit
from study of foetal antigens and related
substances. At present, most tumours
are classified according to their histo-
genesis and behaviour, functional attri-
butes, with the exception of endocrine
tumours, seldom being included. The
finding of new macromolecules, with or
without metabolic activity in or on
tumour cells, may facilitate the develop-
ment of a new era offunctional pathology.
By outlining the immunological spectra,
functional heterogeneity between tumours
of identical light morphology or between
different cells of the same tumour may be
discerned, which could have aetiological
behavioural and prognostic significance.
It would seem to be worth while ascer-
taining if the prognosis of CEA-positive
and CEA-negative tumours is different.
Recent experimental work has related the
metastasizing capacity oftumours to a loss
of surface glycoprotein with the plasma
(Kim and Carruthers, 1972). By follow-
ing up patients after surgery for malignant
disease, it should be feasible to discover if
those tumours associated with raised
plasma levels tend to metastasize earlier
than those with normal levels. This
seems to be true for teratomata and AFP
production (Mawas et al., 1971). The
precise histogenesis of some tumours
remains to be ascertained and knowledge
of the embryonic sites of foetal antigen
production may help with such problems.
As an example, it is not unreasonable to
propose that the so-called endodermal
sinus tumour, if it is of vitelline origin
(Teilum, 1971), should produce AFP.
The immunological diagnosis of neo-
plasia will probably become one of the
major research-orientated aspects of
clinical pathology in the next decade. At
the beginning of this review, we proposed
that foetal antigens would require to fulfil
4 criteria to be of clinical value. Unfor-
tunately, none yet satisfy them all, failing
at least in regard to tumour specificity.
Nonetheless, materials like CEA and AFP
have a clinical role at this point in time,
aiding with diagnosis (especially AFP)
and monitoring the effects oftherapy. It
still remains, however, to be ascertained
if longevity and morbidity will be im-
proved by detecting and treating recurrent
disease earlier than usual.
Most tumours are considered curable
if treated early by surgery, radiotherapy
and/or chemotherapy and hence many
clinical scientists are searching for a
screening test for early cancer. Whether
or not any single material will be found to
fulfil this role is uncertain. Such an
approach is more likely to be fruitful if a
series of different tumour products are
measured. A continuing search for CEA-
like materials in other human tumours
seems warranted. Our own studies (at
the Institute of Cancer Research) have
revealed the presence in some gastro-
intestinal, mammary and bronchial
tumours and the corresponding sera of
another macromolecule which is absent
from, or present only in trace amounts in,
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control tissues. This material (called
" X ") is soluble in perchloric acid, and
occurs either alone or in conjunction with
CEA from which it has been separated.
We are attempting to prepare appropriate
antisera and establish an immunoassay.
By developing radioimmunoassays for
each new tumour product, if preliminary
studies are encouraging, and using them in
conjunction with those includinghormones
or hormonal fragments which are already
established, a battery of tests will become
available which, taken together, may aid
in detection, differential diagnosis and
prognostication.
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